UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary disease (COPD) drug ensifentrine, setting up regulatory filings in the first half of next year.

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Sanofi S.A. Part Cert-1.97% €8.03M ...

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.

You can create a release to package software, along with release notes and links to binary files, for other people to use. Learn more about releases in our docs.